Peakdale announces collaboration to commercialize methathesis-based privileged scaffolds with Materia Inc.

12-Mar-2007

Materia, Inc. and Peakdale Molecular Ltd. announced their collaboration to offer metathesis-based scaffolds for the pharmaceutical industry. Under the agreement, Peakdale has acquired non-exclusive rights to practice Materia's Metathesis intellectual property portfolio for the design, development, and sale of research quantities of the scaffolds. The partners will jointly identify target compounds, while Peakdale will be primarily responsible for the compounds' development, production, and initial distribution.

The collaborators will introduce two new series of privileged scaffolds by the end of 2007, with further series expected to be introduced in 2008. The initial series was selected by Dr. Ray Fisher (Peakdale's Commercial Director) because of its usefulness in exploring novel drug like space and its suitability to synthesis via metathesis.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!

See the theme worlds for related content

Topic world Synthesis

Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

15+ products
4 whitepaper
15+ brochures
View topic world
Topic world Synthesis

Topic world Synthesis

Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

15+ products
4 whitepaper
15+ brochures